In may 2018 Ranger Biotechnologies acquired all assets including the Blockmir Technology platform from former Mirrx Therapeutics. Today the Blockmir Technology is part of a strategic alliance between Ranger and MJJ Biotechnologies, Guangdong, PRC.

The technology uses short highly modified oligonucleotides – Blockmirs – to block specific miRNA binding sites on individual mRNAs. This achieves gene specific upregulation on protein level and sets the Blockmir Technology apart from most other therapeutic modalities which aim to antagonize mRNA or protein activity. Blockmirs are agonists of gene expression and lead to physiologic upregulation of protein levels.

The Blockmir Technology is covered by a broad and dominant portfolio of issued patents. The patent estate covers the target mRNAs of more than 300 miRNAs – which means several thousands of different target mRNAs that can be upregulated individually.  A composition of matter for a general Blockmir design with improved selectivity and potency is also granted.

Upregulation of therapeutically relevant proteins is applicable in a wide range of diseases spanning from cancer to rare genetic and metabolic disorders where even a small upregulation of a single protein can mean a world of difference for the patients. Blockmirs, sometimes called target protectors or protectomirs, have been used in more than 160 academic research programs worldwide, showing upregulation of many therapeutically relevant targets and underscoring the wide application of this technology.

Together with MJJ Biotechnologies we are focused on developing new medicines for diseases of the liver, the CNS and the eye.

In collaboration with academic research groups Ranger Biotechnologies is part of a number of publications on specific Blockmirs and their potential therapeutic use.

Targeting vascular endothelial-cadherin in tumor-associated blood vessels promotes T cell-mediated immunotherapy

Yang Zhao, Kaka Ting, Jia Li, Victoria C Cogger, Jinbiao Chen, Anna Johansson-Percival, Shin Foong Ngiow, Jeff Holst, Georges E. R. Grau, Shom Goel, Thorleif Moller, Elisabetta Dejana, Geoffrey W McCaughan, Mark J. Smyth, Ruth Ganss, Mathew A Vadas and Jennifer R Gamble

Cancer Research DOI: 10.1158/0008-5472.CAN-16-3129

Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin–restricted miRNA antagonists of miR-27

Jennifer A. Young, Ka Ka Ting, Jia Li, Thorleif Moller, Louise Dunn, Ying Lu, Angelina J. Lay, Joshua Moses, Leonel Prado-Lourenço, Levon M. Khachigian, Martin Ng, Philip A. Gregory, Gregory J. Goodall, Anna Tsykin, Ilana Lichtenstein, Christopher N. Hahn, Nham Tran, Nicholas Shackel, James G. Kench, Geoffrey McCaughan, Mathew A. Vadas and Jennifer R. Gamble

Blood 2013 122:2911-2919; doi:

Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models

Ka Ka Ting, Yang Zhao, Weiyong Shen, Paul Coleman, Michelle Yam, Tailoi Chan-Ling, Jia Li, Thorleif Moller, Mark Gillies, Mathew A. Vadas, Jennifer R. Gamble

Diabetologia. 2018 Nov 15. doi: 10.1007/s00125-018-4770-4.

The VE-Cadherin/β-catenin signalling axis regulates immune cell infiltration into tumours
Yang Zhao, Jia Li, KaKa Ting, Jinbiao Chen, Paul Coleman, Ken Liu, Li Wan, Thorleif Moller, Mathew A. Vadas, Jennifer R. Gamble

Cancer Letters, Volume 496, 1 January 2021, Pages 1-15

Targeting miR-27a/VE-cadherin interactions rescues cerebral cavernous malformations in mice

Jia Li Yang Zhao, Jaesung Choi, Ka Ka Ting, Paul Coleman, Jinbiao Chen, Victoria C. Cogger, Li Wan, Zhongsong Shi, Thorleif Moller, Xiangjian Zheng, Mathew A. Vadas, Jennifer R. Gamble

PLOS Biology | June 5, 2020